Várhelyi estimated reforms could lower business costs by 20-25 percent – potentially offsetting the impact of US tariffs and “MFN” pricing.
Asked about the impact of Trump’s so-called ‘most-favoured nation’ pricing, European Health Commissioner Olivér Várhelyi said that Europe’s strategy goes beyond pricing disputes and instead focuses on strengthening innovation, investment, and healthcare access across the EU.
Speaking after the Informal Health Council in Nicosia, Várhelyi stressed that the issue cannot be reduced solely to drug prices or tariffs and that recent regulatory decisions could reduce costs.
“My personal educated guess is that we are achieving between 20 and 25 percent cost reductions,” he said, suggesting that these savings could outweigh the impact of potential tariffs of around 15 percent.
The Commissioner said…
